BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has reported a loss for its first fiscal quarter (ending March 31) of $-0.17 versus a loss $-0.28 for the same period a year ago. E.P.S. were $-1.07 for the latest four quarters through March 31 versus $-1.21 for the same period a year ago.
Recent Price Action
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) stock enjoyed a major increase of 18.4% on 5/6/24. The shares closed at $5.27. Moreover, exceptionally high trading volume at 261% of normal accompanied the advance. The stock has been extremely weak relative to the market over the last nine months but has risen 26.7% during the last week.
Current PriceTarget Research Rating
BCRX is expected to continue to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
BioCryst Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment